BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28731719)

  • 1. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
    Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
    J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent inhibitors of the lysophospholipase autotaxin.
    Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.
    Meegalla SK; Huang H; Illig CR; Parks DJ; Chen J; Lee YK; Wilson KJ; Patel SK; Cheung WS; Lu T; Kirchner T; Askari HB; Geisler J; Patch RJ; Gibbs AC; Rady B; Connelly M; Player MR
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4216-22. PubMed ID: 27491708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
    Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
    J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
    Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
    Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
    Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
    Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
    Fells JI; Lee SC; Fujiwara Y; Norman DD; Lim KG; Tsukahara R; Liu J; Patil R; Miller DD; Kirby RJ; Nelson S; Seibel W; Papoian R; Parrill AL; Baker DL; Bittman R; Tigyi G
    Mol Pharmacol; 2013 Sep; 84(3):415-24. PubMed ID: 23793291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
    Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
    Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
    Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
    Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent research advances in ATX inhibitors: An overview of primary literature.
    Zhang C; Liu Y; Zhou Q; Fan H; Liu X; Hu J
    Bioorg Med Chem; 2023 Jul; 90():117374. PubMed ID: 37354726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-based autotaxin pharmacophore models reflect structure-based docking results.
    Mize CD; Abbott AM; Gacasan SB; Parrill AL; Baker DL
    J Mol Graph Model; 2011 Nov; 31():76-86. PubMed ID: 21967734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autotaxin inhibitors: a patent review (2012-2016).
    Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
    Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
    Banerjee A; Narayana L; Raje FA; Pisal DV; Kadam PA; Gullapalli S; Kumar H; More SV; Bajpai M; Sangana RR; Jadhav S; Gudi GS; Khairatkar-Joshi N; Merugu RR; Voleti SR; Gharat LA
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6747-54. PubMed ID: 24231362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
    Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
    J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, docking and biological evaluation of 4-phenyl-thiazole derivatives as autotaxin (ATX) inhibitors.
    Balupuri A; Lee DY; Lee MH; Chae S; Jung E; Kim Y; Ryu J; Kang NS
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4156-4164. PubMed ID: 28743508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.
    Balupuri A; Lee MH; Chae S; Jung E; Yoon W; Kim Y; Son SJ; Ryu J; Kang DH; Yang YJ; You JN; Kwon H; Jeong JW; Koo TS; Lee DY; Kang NS
    Eur J Med Chem; 2018 Mar; 148():397-409. PubMed ID: 29477073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Potent
    Kawaguchi M; Okabe T; Okudaira S; Hama K; Kano K; Nishimasu H; Nakagawa H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
    J Med Chem; 2020 Mar; 63(6):3188-3204. PubMed ID: 32134652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis.
    Uranbileg B; Ito N; Kurano M; Kano K; Uchida K; Sumitani M; Aoki J; Yatomi Y
    Sci Rep; 2021 Feb; 11(1):3984. PubMed ID: 33597645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
    Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
    J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autotaxin: structure-function and signaling.
    Perrakis A; Moolenaar WH
    J Lipid Res; 2014 Jun; 55(6):1010-8. PubMed ID: 24548887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.